Amgen Aims To Submit NDA for PCSK9 Candidate During “Data-Rich” 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The company now appears to be neck and neck with Regeneron in the race to market the first PCSK9 blocker for high cholesterol, with a filing possible by the end of the year. The drug is part of a deep late-stage pipeline, expected to yield pivotal data on numerous drugs by 2016.